LB-2159

N/A

Report date: 2024/07/05 15:24:48
NME

Base Information

Drug NameLB-2159
Drug Alias NameLB-2159
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsProto-oncogene tyrosine-protein kinase ROS inhibitorsNerve growth factor receptor Trk-A inhibitors
TargetsAnaplastic lymphoma kinaseProto-oncogene tyrosine-protein kinase ROSNerve growth factor receptor Trk-A
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSuzhou Langrui Biomedical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Langrui Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A